Fan Site: Inspired, Not Endorsed, By Rakesh Jhunjhunwala

The Best Pharma Stocks To Buy Now: Karvy



Karvy has identified the best large-cap and mid-cap stocks to buy now




images

Rahul Sharma of Karvy, who is an expert on the pharmaceutical sector, has conducted a detailed analysis of the past quarterly results of the best pharma companies and estimated what their future earnings will be. Based on this analysis, he has identified the stocks that investors should buy, hold or sell. A short reasoning, together with the target price, of each stock recommendation is also given.

Click here to read Karvy’s research report on pharma stocks
investments, Large Cap, Mid Cap, Stock Picks, Top Picks    ,

No Comments Yet

Leave a Reply

Your email address will not be published. Required fields are marked *

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 495 other subscribers

RSS Stocks Talk Forum

  • Sunil Singhania & Madhu Kela are bullish about Himatsingka Seide
    Sunil Singhania & Madhu Kela are bullish about Himatsingka Seide. Singhania's Abakkus Fund holds 6.78% worth ₹137 Cr. Kela's Cohesion MK Fund holds 4.07% worth ₹82 Cr. M-Cap is ₹2100 Cr. Promoters hold 37%. Co is dominant in branded Home Textile with a 'fibre to shelf' model
  • Suraj Estate Developers has a robust project lineup & launch pipeline. TP ₹992 (+73%)
    Suraj Estate Developers has a robust project lineup & launch pipeline, leadership position in redevelopment projects, strong cost advantage, proven track record, huge addressable market and healthy Balance Sheet with predictable cash flows. TP ₹992 (+73%) Download research report... Suraj Estate Developers has a robust project lineup & launch pipeline. TP ₹992 (+73%)
  • DCX Systems has the ability to become a key player in EMS space. TP ₹466 (+54%)
    DCX Systems has the ability to become a key player in EMS space with huge potential in railway & defence. It has ability to deliver high value complicated & critical products for leading defense players L&T & Lockheed. Order book ₹3000 Cr. TP ₹466 (+54%) Download... DCX Systems has the ability to become a key […]
Disclaimer: This is a Fan Site in Rakesh Jhunjhunwala's name. Rakesh Jhunjhunwala is not associated with us and is in no way aware, accountable or responsible for what is stated here. Further, nothing here constiutes investment advice for you to act on. Also, we have a vested interest, and are extremely biased, in everything that we say. So Mind It!